Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avid Bioservices Inc (NQ: CDMO )

19.16 USD +0.23 (+1.24%)
Streaming Delayed Price Updated: 3:39 PM EDT, Apr 13, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 382,026
Open 18.98
Bid (Size) 19.15 (4)
Ask (Size) 19.18 (5)
Prev. Close 18.93
Today's Range 18.81 - 19.36
52wk Range 3.950 - 22.13
Shares Outstanding 55,552,233
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
From GlobeNewswire News Releases
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
From GlobeNewswire News Releases

Performance

YTD
+61.59%
+61.59%
1 Month
+8.40%
+8.40%
3 Month
+51.62%
+51.62%
6 Month
+146.97%
+146.97%
1 Year
+337.56%
+337.56%

More News

Read More
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
From GlobeNewswire News Releases
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments
From GlobeNewswire News Releases
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
From GlobeNewswire News Releases
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021
From GlobeNewswire News Releases
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
From GlobeNewswire News Releases
First Week of CDMO May 21st Options Trading
Tags Stocks
From Market News Video
Terlipressin Formulation with API Manufactured by CPC Scientific Approved for Further Study by the MEB
Tags United States Formulation CDMO
From PRLog
Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
From GlobeNewswire News Releases
Avid Bioservices' Series E Preferred Stock Shares Cross 9% Yield Mark
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.